You are viewing the site in preview mode
Skip to main content
| |
Bone sarcoma
|
Soft tissue sarcoma
|
|---|
| |
Radiotherapy
|
No radiotherapy
|
Radiotherapy
|
No radiotherapy
|
|---|
|
1st cancer type
|
Obs
|
SIR
|
Obs
|
SIR
|
Obs
|
SIR
|
Obs
|
SIR
|
|---|
|
Oral Cavity and Pharynx
|
9
|
7.61*
|
1
|
0.49
|
12
|
1.95*
|
8
|
0.75
|
|
Rectum and Anus
|
6
|
5.15*
|
6
|
1.77
|
12
|
1.82
|
18
|
0.96
|
|
Larynx
|
2
|
1.62
|
2
|
3.80
|
6
|
0.87
|
3
|
1.06
|
|
Lung and Bronchus
|
0
|
0.00
|
4
|
1.48
|
12
|
3.44*
|
19
|
1.30
|
|
Female Breast
|
21
|
2.59*
|
21
|
1.28
|
104
|
2.67*
|
101
|
1.29*
|
|
Cervix Uteri
|
6
|
6.62*
|
1
|
0.71
|
10
|
2.38*
|
6
|
1.04
|
|
Corpus Uteri
|
12
|
3.96*
|
3
|
0.62
|
27
|
1.89*
|
29
|
1.25
|
|
Ovary
|
3
|
13.99*
|
2
|
1.45
|
6
|
6.25*
|
9
|
1.44
|
|
Prostate
|
8
|
1.09
|
19
|
1.38
|
89
|
1.69*
|
97
|
1.05
|
|
Testis
|
0
|
0.00
|
0
|
0.00
|
9
|
2.60*
|
8
|
2.78*
|
|
Brain and CNS
|
3
|
10.47*
|
0
|
0.00
|
4
|
3.66*
|
3
|
3.44
|
|
Thyroid
|
4
|
4.12*
|
2
|
0.91
|
11
|
2.63*
|
10
|
1.04
|
|
Hodgkin Lymphoma
|
3
|
4.28
|
3
|
6.37*
|
22
|
8.71*
|
7
|
3.72*
|
|
Non-Hodgkin Lymphoma
|
10
|
9.00
|
7
|
2.92*
|
11
|
1.96
|
17
|
1.36
|
|
Leukemia
|
1
|
17.60
|
5
|
3.09*
|
1
|
4.17
|
10
|
1.16
|
- *p < 0.05. Obs-observed number of subsequent primary sarcomas. SIR-standardized incidence ratio. Analysis includes adulthood (age 20–79 years at diagnosis) 1+ year survivors of the specified 1st cancer type. Follow-up for second primary bone or soft tissue sarcoma continued to age 85 years. Patients with unknown radiotherapy were excluded.
